Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets [PDF]
, 2003 Although tissue factor (TF), the principial initiator of physiological coagulation and pathological thrombosis, has recently been proposed to be present in human blood, the functional significance and location of the intravascular TF is unknown.
Alex, Meike +9 more
core +1 more source
Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity [PDF]
, 2015 The complex of coagulation factor VIIa (FVIIa), a trypsin-like serine protease, and membrane-bound tissue factor (TF) initiates blood coagulation upon vascular injury.
Gandhi, Prafull S +7 more
core +1 more source
Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity [PDF]
, 2017 Cisplatin-induced ototoxicity is one of the major factors limiting cisplatin chemotherapy. Ototoxicity results from damage to outer hair cells (OHCs) and other regions of the cochlea.
Bhatta, Puspanjali +12 more
core +2 more sources
Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease [PDF]
, 2005 Patients with thrombocytopathy due to storage pool disease mostly suffer from mild bleeding diathesis. However surgical interventions can lead to excess bleeding.
Almeida +10 more
core +3 more sources
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
Discovery of Novel P1 Groups for Coagulation Factor VIIa Inhibition Using Fragment-Based Screening
Journal of Medicinal Chemistry, 2015 Daniel L. Cheney +14 more
openalex +2 more sources
Clinics and Practice, 2015 Symptomatic intracerebral hemorrhage (sICH) occurs in up to 7% of stroke patients treated with thrombolytic therapy. There are limited data on the effectiveness of the reversal agents used for intravenous tissue plasminogen activator related intracranial
Shadi Yaghi +4 more
doaj +1 more source
Journal of the Formosan Medical Association, 2006 Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients with inhibitors. It has also been used to stop bleeding in nonhemophilic patients who fail to respond to conventional treatment.
Yu-Feng Wei +4 more
doaj +1 more source
Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis. [PDF]
, 2018 Background:Recombinant factor VIIa (rFVIIa) has been used off-label as an adjunct in the reversal of warfarin therapy and management of hemorrhage after trauma. Only a handful of these reports are rigorous studies, from which results regarding safety and
Coimbra, Raul +4 more
core +2 more sources
Flux moduli stabilisation, Supergravity algebras and no-go theorems [PDF]
, 2010 We perform a complete classification of the flux-induced 12d algebras compatible with the set of N=1 type II orientifold models that are T-duality invariant, and allowed by the symmetries of the T^6/(Z_2 x Z_2) isotropic orbifold.
A Dabholkar +45 more
core +2 more sources